November 12, 2014—Westminster, CO—The Board of Directors of Surefire Medical, Inc. today announced the appointment of Beverly Huss as a director of the company. Surefire Medical’s novel infusion systems are designed to optimize targeted delivery of embolic agents used in minimally invasive direct-to-target interventional procedures, including radioembolization and chemoembolization.

“Beverly’s experience in developing minimally invasive approaches to treating obesity as an alternative to bariatric surgery, which Surefire Medical is exploring, is a great asset to our company and its plans for growth into new markets,” said James E. Chomas, President and CEO. “We are also very fortunate to benefit from her lengthy experience in bringing to market new, rapidly adopted medical technologies.”

Ms. Huss is President and CEO of therapeutic temperature management startup QooL Therapeutics. Previously, she was CEO of Vibrynt, Inc., a company that developed an innovative minimally invasive therapeutic device for treating morbid obesity. Prior to that she spent 20 years at Guidant Corporation, rising from guide wire engineer to Vice President of several divisions. She managed Guidant’s worldwide Endovascular Solutions business, which quadrupled revenues in her four years at its helm and prior to that built the Guidant’s coronary stent business, the market leader for 27 of 28 quarters. Earlier in her career Ms. Huss held engineering positions at Honeywell’s Defense Systems Division, and at Jones and Laughlin Steel.

“I look forward to working with Surefire Medical’s high caliber Board and a company that is rapidly advancing minimally invasive, target treatments with a unique and very promising interventional approach,” Ms. Huss said.

About Surefire Medical

Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue. The Surefire Infusion System and guiding catheters have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand and Taiwan. www.surefiremedical.com

Achievement

Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer. Study presented at SIR 2017 Annual Scientific Meeting.